ArticleBMC ophthalmology2021
PreserFlo MicroShunt® exposure: a case series.
Article in BMC ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Petrolatum-based ointment application induces swelling of the PRESERFLO Microshunt.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Case Report: Tube perforation after bleb reformation after PreserFlo MicroShunt implantation.Frontiers in ophthalmology · 2026Article
- Wipe-Out Syndrome After PreserFlo MicroShunt Implantation in a Patient With Pseudoexfoliation Glaucoma.Cureus · 2025Article
- Article
- [Severe, acute, purulent conjunctivitis after glaucoma surgery].Die Ophthalmologie · 2025Article
- Short-term efficacy and safety of A-stream glaucoma shunt: a 6-month study.Eye (London, England) · 2025Article
- Anterior Segment Optical Coherence Tomography (AS-OCT) 3D Observation of PreserFlo MicroShunt.Cureus · 2024Article
- Conjunctival Advancement Procedure for Repairing Conjunctival Exposure of the PreserFlo MicroShunt.Cureus · 2024Article
- Scleral bridging technique for preventing PreserFlo microshunt exposure: A case report.Medicine · 2024Article
- [Comparison of new and old procedures in glaucoma surgery : Trabeculectomy, Preserflo and XEN].Die Ophthalmologie · 2023Review
- Safety and Efficacy of the PreserfloJournal of clinical medicine · 2022Article
- Minimally Invasive Glaucoma Surgery: Safety of Individual Devices.Journal of clinical medicine · 2022Review
- Early Complications and Results of Preserflo MicroShunt in the Management of Uncontrolled Open-Angle Glaucoma: A Case Series.International journal of environmental research and public health · 2022Article
- Conjunctival erosion following a PRESERFLO® MicroShunt procedure.American journal of ophthalmology case reports · 2022Article
- PreserFloVision (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreserFlo® MicroShunt (PM) (also known as InnFocus® MicroShunt) is a subconjunctival stent implanted ab externo via a minimally invasive surgical procedure. The current indication is progressive, mild to moderate, open angle glaucoma uncontrolled on topical medications. According to the literature, adverse events are rare, mild and transient. CASE PRESENTATION: Two cases of stand-alone PreserFlo MicroShunt® implantation in patients with uncontrolled open-angle glaucoma are reported. Exposure occurred 7 days and 3 months respectively after implantation. These cases shared common features including preexisting blepharitis and the lack of a Tenon's flap. In both cases, removal of the device was required after several attempts at repair.
conclusionsPreserFlo MicroShunt® exposure is a potentially vision-threatening complication because of the risk of endophthalmitis. Potential risk factors include the absence of a Tenon's flap and pre-existing ocular surface inflammation. Ocular surface inflammation should be detected and treated prior to PM implantation. If a deficiency in Tenon's capsule is noted intraoperatively, close monitoring should be performed because of the higher risk of PM exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.